Full-Time
Posted on 11/7/2025
Global clinical development with flexible CRO
No salary listed
No H1B Sponsorship
Remote in USA
Remote
Catalyst Clinical Research provides customizable clinical trial services to the global biopharmaceutical industry through two offerings: Catalyst Flex, a flexible, globally resourced set of functional services, and Catalyst Oncology, a full-service oncology CRO. These products work by combining a flexible service model with multi-therapeutic resourcing and specialized oncology capabilities, backed by expert teams and technology to tailor each study to the client. It differentiates itself through a decade of customer-centric, people-first culture, global staffing across the US, UK, and Europe, and a focus on adapting services to fit client needs rather than a one-size-fits-all approach. The goal is to help biopharmaceutical programs advance breakthrough clinical development by providing responsive, high-quality resources and services aligned with each project’s requirements.
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
Wilmington, North Carolina
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Worldwide Clinical Trials to acquire Catalyst. The acquisition aims to establish Worldwide as an oncology-focused CRO and expand its global reach for clinical trials. Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research. The transaction will see Catalyst Board chairman Nick Dyer join Worldwide's board of directors while Catalyst president and CEO Nik Morton will become part of Worldwide's executive leadership team. This acquisition aims to establish Worldwide as an oncology-focused CRO while maintaining depth in several therapeutic areas and expanding its global reach for clinical trials. The integration will combine Catalyst's solutions, Catalyst Flex and Catalyst Oncology, with Worldwide's existing portfolio, offering customers expanded services for full-service, functional service provider (FSP) resourcing, and hybrid models. Additionally, the deal includes the adoption of complementary technology platforms and operational practices to enhance data efficiency and visibility across the development lifecycle. Worldwide will acquire Catalyst for an undisclosed sum pending customary closing conditions and regulatory approvals. The transaction is expected to conclude in Q1 2026. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Worldwide is backed by Kohlberg while Catalyst is a portfolio company of QHP Capital. BofA Securities advised Catalyst exclusively; Smith Anderson was its legal counsel. Greenberg Traurig acted as legal counsel for Worldwide. Worldwide CEO Alistair Macdonald said: "Bringing Worldwide and Catalyst together elevates its capabilities in oncology and provides a new solution for its collective customers. "Clinical Trials Arena is excited to add Catalyst's deep operational expertise and oncology credibility to its own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution. Its combined customers seek focused senior executive connection and attention, predictability, speed, flexibility, and scientific rigour. "They will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines while we leverage advanced business management tools and AI to drive operational excellence." In May 2024, Medidata announced an expanded partnership with Worldwide to expedite clinical trials and enhance the patient experience.
Worldwide Clinical Trials has acquired Catalyst Clinical Research, a specialist oncology organisation focused on early-stage cancer trials. The deal expands Worldwide Clinical Trials' capabilities in the oncology sector as the global contract research organisation continues to grow its service offerings.
CRO makes the list for the fifth consecutive yearWILMINGTON, N.C., Aug. 19, 2024 /PRNewswire/ -- Catalyst Clinical Research joined the 2024 Inc. 5000 list of the nation's fastest-growing private companies for its fifth consecutive year. This year Catalyst earned a spot at 2,740 with 185% growth during the past three years."We are honored to be recognized on the Inc. 5000, joining an incredible list of impressive companies. During a period of our global expansion, Catalyst continues to deliver high-quality clinical research services for our clients," says Nik Morton, President and CEO of Catalyst Clinical Research
Kristin Judge assumes leadership role for all commercial functionsWILMINGTON, N.C., Aug. 8, 2024 /PRNewswire/ -- Catalyst Clinical Research announced today that Kristin Judge is its first chief commercial officer (CCO). She assumed the role on July 29, 2024, and leads the company's commercial functions.Kristin Judge, Chief Commercial Officer, Catalyst Clinical Research"Kristin has the depth of commercial experience to support Catalyst's continued growth," said Nik Morton, President and CEO of Catalyst Clinical Research. "Her experience supporting biotech, and pharmaceutical customers with CRO services and life-sciences technologies will be invaluable. She has embraced Catalyst's culture and vision for a differentiated CRO, and will ensure our commercial team is best positioned to deliver strengthened sales performance and continued growth.""Catalyst aligns directly with my strong belief that you can have a company with a positive team culture, people who care about each other, leaders who embrace authenticity, and staff who help customers and thousands of patients and families around the world. What could be better than that?" Ms
Catalyst Clinical Research has named Kristin Judge as its first chief commercial officer (CCO).